(SLP) Simulations Plus - Overview
Stock: Software, Services, Simulation, AI, ADMET
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 61.8% |
| Relative Tail Risk | -23.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.00 |
| Alpha | -72.23 |
| Character TTM | |
|---|---|
| Beta | 0.727 |
| Beta Downside | -0.199 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.66% |
| CAGR/Max DD | -0.37 |
Description: SLP Simulations Plus December 26, 2025
Simulations Plus Inc. (NASDAQ: SLP) creates specialized software that models and simulates drug discovery and development processes, leveraging AI/ML to predict molecular properties. The firm operates through two segments-Software and Services-offering a portfolio that includes GastroPlus (human and animal PK/PD prediction), DDDPlus, MembranePlus, and a suite of mechanistic models such as DILIsym, NAFLDsym, and MITOsym, among others.
Its product line also features an ADMET predictor that ingests molecular structures to forecast absorption, distribution, metabolism, excretion, and toxicity, as well as MedChem Designer and the MonolixSuite for population pharmacokinetic/pharmacodynamic modeling, rapid clinical-trial analysis, and regulatory submission support. Consulting services round out the offering, covering exposure-response analyses, clinical-trial simulations, data programming, and technical writing for pharma, biotech, agro-chemical, cosmetics, food companies, academia, and regulators.
From a financial perspective, SLP reported FY 2023 revenue of roughly $78 million, reflecting a year-over-year growth rate of about 23%, while R&D expenses remained near 15% of revenue-indicative of continued investment in expanding its AI-driven capabilities. The broader health-care-technology market for drug-discovery software is projected to exceed $5 billion by 2028, driven by increasing regulatory demands for early ADMET assessment and the industry’s accelerating adoption of machine-learning models.
Given these dynamics, analysts looking for a data-rich, high-growth niche may find ValueRay’s coverage of SLP a useful next step for deeper quantitative insight.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -64.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 11.95 > 1.0 |
| NWC/Revenue: 60.76% < 20% (prev 41.19%; Δ 19.56% < -1%) |
| CFO/TA 0.17 > 3% & CFO 23.6m > Net Income -64.2m |
| Net Debt (-29.6m) to EBITDA (12.6m): -2.35 < 3 |
| Current Ratio: 5.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.2m) vs 12m ago -0.23% < -2% |
| Gross Margin: 59.60% > 18% (prev 0.58%; Δ 5902 % > 0.5%) |
| Asset Turnover: 47.01% > 50% (prev 37.80%; Δ 9.20% > 0%) |
| Interest Coverage Ratio: 0.09 > 6 (EBITDA TTM 12.6m / Interest Expense TTM 75.4m) |
Altman Z'' -1.58
| A: 0.35 (Total Current Assets 58.1m - Total Current Liabilities 10.3m) / Total Assets 137.8m |
| B: -0.24 (Retained Earnings -33.7m / Total Assets 137.8m) |
| C: 0.04 (EBIT TTM 6.68m / Avg Total Assets 167.4m) |
| D: -3.17 (Book Value of Equity -33.9m / Total Liabilities 10.7m) |
| Altman-Z'' Score: -1.58 = D |
Beneish M -3.90
| DSRI: 0.90 (Receivables 12.2m/12.8m, Revenue 78.7m/74.4m) |
| GMI: 0.98 (GM 59.60% / 58.47%) |
| AQI: 0.73 (AQ_t 0.57 / AQ_t-1 0.78) |
| SGI: 1.06 (Revenue 78.7m / 74.4m) |
| TATA: -0.64 (NI -64.2m - CFO 23.6m) / TA 137.8m) |
| Beneish M-Score: -3.90 (Cap -4..+1) = AAA |
What is the price of SLP shares?
Over the past week, the price has changed by -13.74%, over one month by -24.39%, over three months by -17.73% and over the past year by -59.05%.
Is SLP a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SLP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.7 | 69.3% |
| Analysts Target Price | 24.7 | 69.3% |
| ValueRay Target Price | 11.1 | -24.2% |
SLP Fundamental Data Overview February 04, 2026
P/S = 4.2943
P/B = 2.677
P/EG = 9.7712
Revenue TTM = 78.7m USD
EBIT TTM = 6.68m USD
EBITDA TTM = 12.6m USD
Long Term Debt = 557.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 179.0k USD (from shortTermDebt, last quarter)
Debt = 557.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.6m USD (from netDebt column, last quarter)
Enterprise Value = 302.7m USD (337.9m + Debt 557.0k - CCE 35.7m)
Interest Coverage Ratio = 0.09 (Ebit TTM 6.68m / Interest Expense TTM 75.4m)
EV/FCF = 13.47x (Enterprise Value 302.7m / FCF TTM 22.5m)
FCF Yield = 7.43% (FCF TTM 22.5m / Enterprise Value 302.7m)
FCF Margin = 28.57% (FCF TTM 22.5m / Revenue TTM 78.7m)
Net Margin = -81.66% (Net Income TTM -64.2m / Revenue TTM 78.7m)
Gross Margin = 59.60% ((Revenue TTM 78.7m - Cost of Revenue TTM 31.8m) / Revenue TTM)
Gross Margin QoQ = 59.12% (prev 56.38%)
Tobins Q-Ratio = 2.20 (Enterprise Value 302.7m / Total Assets 137.8m)
Interest Expense / Debt = 131.9% (Interest Expense 734.8k / Debt 557.0k)
Taxrate = 30.31% (294.0k / 970.0k)
NOPAT = 4.65m (EBIT 6.68m * (1 - 30.31%))
Current Ratio = 5.62 (Total Current Assets 58.1m / Total Current Liabilities 10.3m)
Debt / Equity = 0.00 (Debt 557.0k / totalStockholderEquity, last quarter 127.1m)
Debt / EBITDA = -2.35 (Net Debt -29.6m / EBITDA 12.6m)
Debt / FCF = -1.32 (Net Debt -29.6m / FCF TTM 22.5m)
Total Stockholder Equity = 141.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.39% (Net Income -64.2m / Total Assets 137.8m)
RoE = -45.47% (Net Income TTM -64.2m / Total Stockholder Equity 141.3m)
RoCE = 4.71% (EBIT 6.68m / Capital Employed (Equity 141.3m + L.T.Debt 557.0k))
RoIC = 3.29% (NOPAT 4.65m / Invested Capital 141.3m)
WACC = 8.58% (E(337.9m)/V(338.4m) * Re(8.59%) + (debt cost/tax rate unavailable))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF Debug] Terminal Value 76.52% ; FCFF base≈16.9m ; Y1≈17.5m ; Y5≈19.8m
Fair Price DCF = 16.87 (EV 310.3m - Net Debt -29.6m = Equity 339.9m / Shares 20.1m; r=8.58% [WACC]; 5y FCF grow 3.39% → 2.90% )
EPS Correlation: -30.63 | EPS CAGR: -17.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 77.15 | Revenue CAGR: 6.02% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-05-31): EPS=0.32 | Chg30d=+0.020 | Revisions Net=+3 | Analysts=6
EPS current Year (2026-08-31): EPS=1.02 | Chg30d=+0.006 | Revisions Net=-1 | Growth EPS=-0.7% | Growth Revenue=+1.6%
EPS next Year (2027-08-31): EPS=1.06 | Chg30d=-0.037 | Revisions Net=-4 | Growth EPS=+4.1% | Growth Revenue=+6.1%